Allergan and Novartis to collaborate on new NASH therapy trials

Allergan is set to expand its research and development programme on non-alcoholic steatohepatitis (NASH) through a partnership with Novartis that will test a new combination therapy approach for the condition. The pharmaceutical firms have signed a clinical trial agreement under which Novartis will carry out a Phase IIb study testing Allergan’s cenicriviroc (CVC), a once-daily,

Continue Reading

Allergan’s Botox gets EU approval for Incontinence

Allergan has been boosted by the news that Botox has received a positive agreement for approval in 14 European Union countries for treating certain patients with urinary incontinence. The recommendation from the Irish Medicines Board is for Botox (botulinum toxin type A) to be approved for the management of urinary incontinence in adults with neurogenic

Continue Reading